NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Grand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
NEWS Innovative method could offer cost-effective sterilisation approach
19 March 2024
In 2023, Russia has registered 540 drugs
19 March 2024
Rapid pseudomonas aeruginosa detection method developed
18 March 2024
Health Ministry has approved a drug for the treatment of Niemann–Pick disease
18 March 2024